Tags: FDA | generic | drugs | fees

FDA, Industry Reach Generic Drug Fee Agreement

Monday, 15 Aug 2011 02:47 PM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
WASHINGTON — U.S. regulators and generic drugmakers have reached a compromise agreement for a user-fee program that would require the companies to pay nearly $300 million in the first year to accelerate drug approvals.

The Food and Drug Administration has been in negotiations with the generic drug industry since February to establish a user-fee program similar to one in place for brand-name drugs and medical devices.

Through the program, companies would pay fees to give the FDA extra money to hire more staff and improve support systems in its drug review process. Some of the fees would pay for bulking up FDA inspection of U.S. and foreign manufacturing facilities.

The FDA and several industry groups met three times in July, according to meeting notes posted on the FDA's website, and agreed that the industry would fund the user-fee program in full starting in year one.

That would amount to $299 million a year or more, if adjusted for inflation, with some of the first-year money coming from a one-time payment by those companies whose drugs are pending review in FDA's application backlog.

More than two-thirds of all U.S. prescriptions are filled with generic drugs. They have become a formidable rival to brand-name drugs that are facing expiring patents.

With bigger revenues, the generic drug industry is becoming more willing to pay for faster approval of its products. It is also eager for the FDA to improve its inspections to avoid such scandals as the 2008 recall of blood thinning drug heparin after at least 149 people died from tainted ingredients tracked to China.

Similar to the other user-fee programs, Congress would have to give its approval before generic drug user fees are enacted.

The FDA-industry agreements reached in July continue to assume that congressional budget appropriations funding the generics review would remain relatively stable.

Industry representatives in the negotiations included the Generic Pharmaceutical Association, the European Fine Chemicals Group and the Society of Chemical Manufacturers and Affiliates Inc's Bulk Pharmaceuticals Task Force. They represent such companies as Watson Pharmaceuticals, Teva Pharmaceutical Industries and Mylan Labs.

The FDA will convene a public meeting on the issue on Aug. 25.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Jerry Boykin: Army Wrong to Punish Chaplain for Spiritual Advice

Friday, 19 Dec 2014 11:27 AM

The Army violated a chaplain's constitutional right of religious freedom , and its own rules , by reprimanding him for g . . .

Opening With Cuba Raises Risks to Florida's Borders

Friday, 19 Dec 2014 09:38 AM

President Obama's announcement on Wednesday that the United States would normalize relations with Cuba will significantl . . .

WSJ: Cigar Lovers Still Face Long Wait To Puff a Cohiba

Friday, 19 Dec 2014 09:33 AM

Cigar aficionados who are dreaming of puffing on a nice Cohiba following the White House‚Äôs shift in Cuba policy are like . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved